Cargando…
Combination of cetuximab and PP242 synergistically suppress the progression of wild-type KRAS colorectal carcinoma
Mammalian target of rapamycin (mTOR) has been shown to be overactive in human colorectal cancer, but the first-generation mTOR inhibitor, rapamycin, has failed to show clinical efficacy against colorectal cancer. On the other hand, although the second-generation mTOR inhibitor, PP242, has exerted su...
Autores principales: | Cheng, Lei, Xia, Zuguang, Bian, Xinyu, Li, Guangchao, Hu, Jing, Cao, Ya, Wang, Qing, Qian, Xiaoping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636092/ https://www.ncbi.nlm.nih.gov/pubmed/26586952 http://dx.doi.org/10.2147/OTT.S82453 |
Ejemplares similares
-
Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma
por: LAM, KA ON, et al.
Publicado: (2013) -
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
por: Dunn, Emily F., et al.
Publicado: (2010) -
Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
por: Baker, J B, et al.
Publicado: (2011) -
EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy
por: Uhlyarik, Andrea, et al.
Publicado: (2020) -
A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAF(V600) wild-type colorectal cancer
por: Georgiou, Alexandros, et al.
Publicado: (2021)